BRPI0810646A2 - " compostos farmacêuticos ". - Google Patents
" compostos farmacêuticos ".Info
- Publication number
- BRPI0810646A2 BRPI0810646A2 BRPI0810646-0A2A BRPI0810646A BRPI0810646A2 BR PI0810646 A2 BRPI0810646 A2 BR PI0810646A2 BR PI0810646 A BRPI0810646 A BR PI0810646A BR PI0810646 A2 BRPI0810646 A2 BR PI0810646A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical compounds
- pharmaceutical
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0707086A GB0707086D0 (en) | 2007-04-12 | 2007-04-12 | Pharmaceutical compounds |
| GB0707613A GB0707613D0 (en) | 2007-04-19 | 2007-04-19 | Pharmaceutical compounds |
| PCT/GB2008/001292 WO2008125833A1 (en) | 2007-04-12 | 2008-04-14 | Pharmaceutical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0810646A2 true BRPI0810646A2 (pt) | 2014-11-04 |
Family
ID=39590902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0810646-0A2A BRPI0810646A2 (pt) | 2007-04-12 | 2008-04-14 | " compostos farmacêuticos ". |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20100256143A1 (pt) |
| EP (1) | EP2146981A1 (pt) |
| JP (1) | JP2010523637A (pt) |
| KR (1) | KR20100016431A (pt) |
| CN (1) | CN101790525A (pt) |
| AU (1) | AU2008237715A1 (pt) |
| BR (1) | BRPI0810646A2 (pt) |
| CA (1) | CA2683619A1 (pt) |
| IL (1) | IL201366A0 (pt) |
| MX (1) | MX2009010881A (pt) |
| WO (1) | WO2008125833A1 (pt) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008023159A1 (en) | 2006-08-24 | 2008-02-28 | Astrazeneca Ab | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
| WO2009007750A1 (en) | 2007-07-09 | 2009-01-15 | Astrazeneca Ab | Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k |
| JP2010533161A (ja) * | 2007-07-09 | 2010-10-21 | アストラゼネカ アクチボラグ | 化合物−９４６ |
| US8163763B2 (en) | 2008-07-31 | 2012-04-24 | Genentech, Inc. | Pyrimidine compounds, compositions and methods of use |
| WO2010030027A1 (en) * | 2008-09-10 | 2010-03-18 | Mitsubishi Tanabe Pharma Corporation | Aromatic nitrogen-containing 6-membered ring compounds and their use |
| TWI378933B (en) | 2008-10-14 | 2012-12-11 | Daiichi Sankyo Co Ltd | Morpholinopurine derivatives |
| WO2011058027A2 (en) | 2009-11-12 | 2011-05-19 | F. Hoffmann-La Roche Ag | N-9-substituted purine compounds, compositions and methods of use |
| ES2567168T3 (es) | 2009-11-12 | 2016-04-20 | F. Hoffmann-La Roche Ag | Compuestos purina y pirazolopirimidina N7-sustituidos, composiciones y métodos de utilización |
| WO2011080568A2 (en) * | 2009-12-28 | 2011-07-07 | Development Center For Biotechnology | Novel pyrimidine compounds as mtor and p13k inhibitors |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| SA111320519B1 (ar) | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| DE102010049595A1 (de) * | 2010-10-26 | 2012-04-26 | Merck Patent Gmbh | Chinazolinderivate |
| JP5813785B2 (ja) | 2011-02-04 | 2015-11-17 | デュケイン ユニバーシティー オブ ザ ホリー スピリット | 抗チューブリン活性を有する二環式および三環式のピリミジンチロシンキナーゼ阻害剤ならびに患者の処置方法 |
| US9163008B2 (en) * | 2011-09-02 | 2015-10-20 | Purdue Pharma, L.P. | Pyrimidines as sodium channel blockers |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| ES2661510T3 (es) | 2011-12-15 | 2018-04-02 | Novartis Ag | Uso de inhibidores de la actividad o función de PI3K |
| CN104350144B (zh) | 2012-05-23 | 2017-08-04 | 弗·哈夫曼-拉罗切有限公司 | 获得和使用内胚层和肝细胞的组合物和方法 |
| WO2014068070A1 (en) | 2012-10-31 | 2014-05-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for preventing antiphospholipid syndrome (aps) |
| WO2016059220A1 (en) | 2014-10-16 | 2016-04-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Tcr-activating agents for use in the treatment of t-all |
| WO2018218197A2 (en) | 2017-05-26 | 2018-11-29 | Board Of Regents, The University Of Texas System | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase |
| US10377591B2 (en) | 2017-07-07 | 2019-08-13 | Zebra Technologies Corporation | Input handling for media processing devices |
| HRP20240368T1 (hr) * | 2017-07-13 | 2024-08-30 | Board Of Regents, The University Of Texas System | Heterociklički inhibitori atr kinaze |
| JP7290627B2 (ja) * | 2017-08-17 | 2023-06-13 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | Ａｔｒキナーゼの複素環式阻害剤 |
| CN109810100B (zh) * | 2017-11-21 | 2022-03-11 | 中国药科大学 | 含有苯并呋喃的parp-1和pi3k双靶点抑制剂 |
| US11498901B2 (en) | 2018-03-02 | 2022-11-15 | Firmenich Sa | Hydrogenation of imines with Ru complexes |
| JP7341156B2 (ja) | 2018-03-16 | 2023-09-08 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | Ａｔｒキナーゼの複素環式阻害剤 |
| CN109942562B (zh) * | 2019-02-27 | 2022-02-08 | 江西科技师范大学 | 含芳基结构的五元杂环联三嗪类化合物及其制备方法和应用 |
| EP3967694A4 (en) * | 2019-06-06 | 2022-12-07 | Beijing Tide Pharmaceutical Co., Ltd. | 2, 4, 6-TRI-SUBSTITUTED PYRIMIDINE COMPOUND AS ATR-KINASE INHIBITOR |
| EP3931176B1 (en) | 2019-08-08 | 2024-02-14 | Firmenich SA | Hydrogenation of imines with ru complexes |
| EP4155307A4 (en) | 2020-05-20 | 2023-09-13 | Beijing Tide Pharmaceutical Co., Ltd. | 2,4,6-TRIS-SUBSTITUTED PYRIMIDINE COMPOUNDS AS ATR KINASE INHIBITORS |
| CN113135900B (zh) * | 2021-03-12 | 2022-05-24 | 中山大学 | 吲哚嘧啶类化合物及其合成方法和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2316831T3 (da) * | 2002-11-21 | 2013-06-10 | Novartis Ag | 2-(Morpholin-4-yl)pyrimidiner som phosphotidylinositol (PI)-3-kinaseinhibitorer samt deres anvendelse ved behandling af cancer |
| KR20080083188A (ko) * | 2006-01-11 | 2008-09-16 | 아스트라제네카 아베 | 모르폴리노 피리미딘 유도체 및 요법에서의 그 유도체의용도 |
| US20100130496A1 (en) * | 2007-04-12 | 2010-05-27 | F. Hoffmann-La Roche Ag | Pyrimidine derivatives as inhibitors of phosphatidylinositol-3-kinase |
-
2008
- 2008-04-14 JP JP2010502574A patent/JP2010523637A/ja active Pending
- 2008-04-14 CA CA002683619A patent/CA2683619A1/en not_active Abandoned
- 2008-04-14 WO PCT/GB2008/001292 patent/WO2008125833A1/en not_active Ceased
- 2008-04-14 AU AU2008237715A patent/AU2008237715A1/en not_active Abandoned
- 2008-04-14 US US12/594,543 patent/US20100256143A1/en not_active Abandoned
- 2008-04-14 KR KR1020097023502A patent/KR20100016431A/ko not_active Withdrawn
- 2008-04-14 BR BRPI0810646-0A2A patent/BRPI0810646A2/pt not_active Application Discontinuation
- 2008-04-14 EP EP08736956A patent/EP2146981A1/en not_active Withdrawn
- 2008-04-14 MX MX2009010881A patent/MX2009010881A/es unknown
- 2008-04-14 CN CN200880019760A patent/CN101790525A/zh active Pending
-
2009
- 2009-10-11 IL IL201366A patent/IL201366A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL201366A0 (en) | 2010-05-31 |
| CN101790525A (zh) | 2010-07-28 |
| WO2008125833A1 (en) | 2008-10-23 |
| JP2010523637A (ja) | 2010-07-15 |
| KR20100016431A (ko) | 2010-02-12 |
| US20100256143A1 (en) | 2010-10-07 |
| MX2009010881A (es) | 2009-12-14 |
| AU2008237715A1 (en) | 2008-10-23 |
| CA2683619A1 (en) | 2008-10-23 |
| EP2146981A1 (en) | 2010-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2018030I1 (el) | Φαρμακοτεχνικη μορφη 514 | |
| BRPI0810928A2 (pt) | "composição farmacêutica" | |
| DK2041139T3 (da) | Farmaceutiske forbindelser | |
| DE602007009284D1 (de) | 3-aza-bicycloä3.1.0ühexanderivate | |
| ATE469145T1 (de) | 4-ä5-methoxy-6-(2-methyl-6-ä1,2,4ütriazol-1-yl- | |
| DK1907037T3 (da) | Medikamentdispenser. | |
| BRPI0816970A2 (pt) | 1,3-dissubstituídas-4-fenil-1h-piridin-2-onas | |
| BRPI0714539A2 (pt) | "formas farmacêuticas" | |
| EP1903866A4 (en) | IMPROVED RELEASE OF TETRAHYDROCANNABINOL | |
| BRPI0719626A2 (pt) | '' composto '' | |
| BRPI0815717A2 (pt) | Compostos de imidazopirazina. | |
| BRPI0922904A2 (pt) | "compostos" | |
| NL2000480A1 (nl) | Nieuwe farmaceutische middelen. | |
| BRPI0811718A2 (pt) | Derivados de 3,3-espiroindolinona | |
| DK2205562T3 (da) | 1,1,1-trifluor-2-hydroxy-3-phenylpropanderivater | |
| NL2000581A1 (nl) | Aangecondenseerde fenylamidoheterocyclische verbindingen. | |
| RU2398586C3 (ru) | Фармацевтическая композиция | |
| BRPI0812354A2 (pt) | Composição farmacêutica não-aquosa. | |
| CR10353A (es) | Nuevos compuestos. | |
| DE602007001681D1 (de) | 1,3-dioxan-carboxylsäuren | |
| DK1957073T3 (da) | Lægemiddel | |
| BRPI0812460A2 (pt) | " compostos orgânicos ". | |
| BRPI0819546A2 (pt) | "capacitor" | |
| FR2913694B1 (fr) | Elements regulateurs d'expression | |
| BRPI0811431A2 (pt) | Composição farmacêutica aquosa. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |